Lu, Yi
Ganz, Michael L.
Robinson, Rebecca L.
Zagar, Anthony J.
Okala, Sandra
Hartrick, Craig T.
Johnston, Beth
Dorling, Patricia
Slim, May
Thakkar, Sheena
Berger, Ariel
Funding for this research was provided by:
Eli Lilly and Company
Pfizer
Article History
Received: 19 July 2022
Accepted: 6 June 2023
First Online: 30 June 2023
Declarations
:
: The curated administrative healthcare data (i.e., electronic medical records, claims data) used are pseudonymized without identifiable personal information. An ethic approval was not required for the use of pseudonymized administration healthcare data, due to 1) all data were pre-collected by respective healthcare systems and used retrospectively; (2) the current study is observation (i.e., non-interventional); and (3) all data used are de-identified.In addition to curated administrative healthcare data, supplementary data on disease assessment and treatment are abstracted from study participants’ existing medical chart retrospectively and does not contain any identifiable or socio-demographic information. Institutional Review Board (IRB) approval was obtained for the chart review from the two respective healthcare systems used in this study – Henry Ford Health System (IRB No: 13695) and Reliant Medical Group (IRB No: 2609) before commencing the study. Ethics committee (i.e., the IRB) of Henry Ford Health System and Reliant Medical Group waived the need for informed consent since the chart review was performed retrospectively and contains only de-identifiable information. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: RLR, AJZ and BJ are employees and shareholders of Eli Lilly and Company. AB, MLG, YL, and SO are employees of Evidera, which received funding from Pfizer and Eli Lilly and Company to conduct the study; MLG is also a shareholder of Thermo Fisher Scientific. PD and ST are employees of Pfizer with stock and/or stock options. CTH is an employee of Algosunesis, LLC. MS was an Evidera employee at the time of study execution and is currently employed by Duchesnay.